Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anhydramnios”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Not applicableLooking for participantsNCT06728228
What this trial is testing

Amnioinfusion for Fetal Renal Failure

Who this might be right for
Multicystic Dysplastic KidneyPolycystic Kidney DiseaseFetal Renal Anomaly+6 more
Fetal Care Center, PLLC 35
Early research (Phase 1)Active Not RecruitingNCT03101891
What this trial is testing

Renal Anhydramnios Fetal Therapy

Who this might be right for
AnhydramniosPotter SyndromeLung Hypoplasia+4 more
Johns Hopkins University 70
Large-scale testing (Phase 3)Looking for participantsNCT04782258
What this trial is testing

See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)

Who this might be right for
Autosomal Recessive Polycystic Kidney (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc. 20
Large-scale testing (Phase 3)WithdrawnNCT04786574
What this trial is testing

See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Who this might be right for
Autosomal Recessive Polycystic Kidney Disease (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc.